GlassScriptPhysician profile
Bradley J Davis
NPI 1326203548
$7,991.39
in general payments reported to CMS, 2019-2025
40 companies · $1,770 in 2025
The $1,770 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $344 · 2020: $583 · 2021: $846 · 2022: $1,105 · 2023: $1,647 · 2024: $1,696 · 2025: $1,770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,113.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,250.21 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,145.56 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $825.92 | 2019-2025 | |
| Abbott Laboratories | $744.41 | 2021-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $711.32 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $667.24 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $427.28 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $245.34 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Xeris Pharmaceuticals, INC. | $206.51 | 2021-2025 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $192.90 | 2021-2024 | Xarelto |
| Vanda Pharmaceuticals INC. | $182.13 | 2024-2025 | Fanapt |
| Bayer Healthcare Pharmaceuticals INC. | $153.98 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $144.28 | 2021-2023 | Camzyos |
| Biohaven Pharmaceutical Holding Company LTD. | $124.44 | 2022 | |
| Novartis Pharmaceuticals Corporation | $103.84 | 2021-2023 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.